Natixis Advisors LLC Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Natixis Advisors LLC reduced its stake in DexCom, Inc. by 22% during the first quarter, bringing their ownership to 150,944 shares valued at approximately $10.3 million.
• Investors like Federated Hermes Inc. have significantly increased their holdings in DexCom, growing their stake by 2,371.4% during the same period.
• DexCom reported an EPS of $0.48 for the last quarter, exceeding analysts' estimates, and showed 15.2% revenue growth year-over-year, totaling $1.16 billion.

Natixis Advisors LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 22.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 150,944 shares of the medical device company's stock after selling 42,588 shares during the quarter. Natixis Advisors LLC's holdings in DexCom were worth $10,308,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Golden State Wealth Management LLC raised its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Optiver Holding B.V. purchased a new position in shares of DexCom in the 4th quarter worth $33,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth about $38,000. Alpine Bank Wealth Management purchased a new position in shares of DexCom during the 1st quarter worth about $40,000. Finally, Private Trust Co. NA boosted its position in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares during the period. Institutional investors own 97.75% of the company's stock.

DexCom Price Performance

DXCM traded up $0.94 on Wednesday, reaching $76.40. 4,827,560 shares of the company's stock were exchanged, compared to its average volume of 3,924,715. The stock has a market cap of $29.96 billion, a PE ratio of 53.06, a P/E/G ratio of 1.60 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock's fifty day moving average price is $84.21 and its 200-day moving average price is $80.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president directly owned 109,621 shares in the company, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,656 shares of company stock valued at $2,412,191. Company insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on DXCM shares. Oppenheimer boosted their price objective on shares of DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Piper Sandler boosted their price objective on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. Wall Street Zen raised shares of DexCom from a "buy" rating to a "strong-buy" rating in a research report on Saturday. The Goldman Sachs Group assumed coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price objective for the company. Finally, William Blair upgraded shares of DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.